{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:55Z","timestamp":1777680055321,"version":"3.51.4"},"reference-count":18,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Hosp Pharm"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1310\/hpj5108-611","type":"journal-article","created":{"date-parts":[[2016,9,20]],"date-time":"2016-09-20T17:35:52Z","timestamp":1474392952000},"page":"611-614","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Surrogate Markers and Drug Approvals"],"prefix":"10.1177","volume":"51","author":[{"given":"Danial E.","family":"Baker","sequence":"first","affiliation":[{"name":"Drug Information Center, College of Pharmacy, Washington State University Spokane."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2016,8,1]]},"reference":[{"key":"bibr1-hpj5108-611","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706628"},{"key":"bibr2-hpj5108-611","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1508120"},{"key":"bibr3-hpj5108-611","unstructured":"Afstyla (antihemophilic factor (recombinant), single chain) [prescribing information]. Kankakee, IL: CSL Behring LLC; May 2016. http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/BloodBloodProducts\/ApprovedProducts\/LicensedProductsBLAs\/FractionatedPlasmaProducts\/UCM503560.pdf"},{"key":"bibr4-hpj5108-611","unstructured":"Cabometyx (cabozantinib) [prescribing information]. South San Francisco, CA: Exelixis, Inc.; April 2016. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208692s000lbl.pdf"},{"key":"bibr5-hpj5108-611","unstructured":"Cinqair (reslizumab) [prescribing information] Frazer, PA: Teva Respiratory, LLC; March 2016. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761033lbl.pdf"},{"key":"bibr6-hpj5108-611","unstructured":"Descovy (emtricitabine\/tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; April 2016. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208215s000lbl.pdf"},{"key":"bibr7-hpj5108-611","unstructured":"Clinical Guidelines Portal: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. ADISinfo website. Published January 28, 2016. https:\/\/aid-sinfo.nih.gov\/guidelines\/html\/1\/adult-and-adolescent-arv-guidelines\/9\/treatment-goals. Accessed July 11, 2016."},{"key":"bibr8-hpj5108-611","unstructured":"Evomela (melphalan) [prescribing information]. Irvine, CA: Spectrum Pharmaceuticals; March 2016. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/207155s000lbl.pdf"},{"key":"bibr9-hpj5108-611","unstructured":"Idelvion [Coagulation Factor IX (Recombinant), Albumin Fusion Protein] [prescribing information]. Kankakee, IL: CSL Behring LLC; March 2016. http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/BloodBloodProducts\/ApprovedProducts\/LicensedProductsBLAs\/FractionatedPlasmaProducts\/UCM489301.pdf"},{"key":"bibr10-hpj5108-611","unstructured":"Inflectra (infliximab-dyyb) [prescribing information]. Lake Forest, IL: Celltrion, Inc.; April 2016. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/labeV2016\/125544s000lbl.pdf"},{"key":"bibr11-hpj5108-611","unstructured":"Kovaltry [Antihemophilic Factor (Recombinant)] [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; March 2016. http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/BloodBloodProducts\/ApprovedProducts\/LicensedProductsBLAs\/FractionatedPlasmaProducts\/UCM491118.pdf"},{"key":"bibr12-hpj5108-611","unstructured":"Nuplazid (pimavanserin) [prescribing information]. San Diego, CA: Acadia Pharmaceuticals, Inc.; April 2016. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/20167207318lbl.pdf"},{"key":"bibr13-hpj5108-611","unstructured":"Ocaliva (obeticholic acid) [prescribing information] New York: Intercept Pharmaceuticals; May 2016. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/207999s000lbl.pdf"},{"key":"bibr14-hpj5108-611","unstructured":"Odefsey (emtricitabine\/rilpivirine hydrochloride\/tenofovir alafenamide fumarate) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; March 2016. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208351s000lbl.pdf"},{"key":"bibr15-hpj5108-611","unstructured":"Taltz (ixekizumab) [prescribing information]. Indianapolis, IN: Eli Lilly and Co.; March 2016. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/125521s000lbl.pdf"},{"key":"bibr16-hpj5108-611","unstructured":"Tecentriq (atezolizumab) [prescribing information]. South San Francisco, CA: Genentech, Inc.; May 2016. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761034Origls000lbl.pdf"},{"key":"bibr17-hpj5108-611","unstructured":"Venclexta (venetoclax) [prescribing information]. North Chicago, IL: AbbVie, Inc.; April 2016. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208573s000lbl.pdf"},{"key":"bibr18-hpj5108-611","unstructured":"Zinbryta (daclizumab) [prescribing information]. Cambridge, MA: Biogen; May 2016. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761029s000lbl.pdf"}],"container-title":["Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1310\/hpj5108-611","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1310\/hpj5108-611","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1310\/hpj5108-611","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:34:20Z","timestamp":1777451660000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1310\/hpj5108-611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,1]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1310\/hpj5108-611"],"URL":"https:\/\/doi.org\/10.1310\/hpj5108-611","relation":{},"ISSN":["0018-5787","1945-1253"],"issn-type":[{"value":"0018-5787","type":"print"},{"value":"1945-1253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,1]]}}}